Pacer Advisors
UTHR icon

Pacer Advisors’s United Therapeutics UTHR Stock Holding History

Pacer Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$144M Buy
243,545
+1,673
+0.7% +$833K 0.41% 61
2025
Q4 		$118M Sell
241,872
-97,199
-29% -$45.3M 0.3% 74
2025
Q3 		$142M Sell
339,071
-170,666
-33% -$57.4M 0.36% 66
2025
Q2 		$146M Sell
509,737
-38,355
-7% -$11.5M 0.36% 62
2025
Q1 		$169M Sell
548,092
-49,542
-8% -$17M 0.4% 61
2024
Q4 		$211M Buy
597,634
+30,931
+5% +$11.4M 0.45% 61
2024
Q3 		$203M Buy
566,703
+4,869
+0.9% +$1.64M 0.43% 62
2024
Q2 		$179M Buy
561,834
+92,240
+20% +$24.4M 0.41% 64
2024
Q1 		$108M Buy
469,594
+156,795
+50% +$35.4M 0.25% 115
2023
Q4 		$68.8M Buy
312,799
+67,738
+28% +$15.6M 0.19% 132
2023
Q3 		$55.4M Buy
245,061
+31,633
+15% +$7.29M 0.21% 118
2023
Q2 		$47.1M Buy
213,428
+41,327
+24% +$9.15M 0.19% 114
2023
Q1 		$38.5M Buy
172,101
+161,777
+1,567% +$39.9M 0.16% 117
2022
Q4 		$2.87M Sell
10,324
-73,681
-88% -$18.6M 0.01% 512
2022
Q3 		$17.6M Sell
84,005
-18,308
-18% -$4.09M 0.12% 135
2022
Q2 		$24.1M Buy
102,313
+49,493
+94% +$10.1M 0.18% 106
2022
Q1 		$9.48M Buy
52,820
+48,176
+1,037% +$9.18M 0.08% 254
2021
Q4 		$1M Sell
4,644
-13,092
-74% -$2.57M 0.01% 1192
2021
Q3 		$3.27M Buy
17,736
+1,031
+6% +$203K 0.04% 557
2021
Q2 		$3M Buy
16,705
+3,306
+25% +$630K 0.04% 498
2021
Q1 		$2.24M Sell
13,399
-724
-5% -$121K 0.04% 481
2020
Q4 		$2.14M Sell
14,123
-7,107
-33% -$933K 0.04% 424
2020
Q3 		$2.14M Buy
21,230
+12,826
+153% +$1.41M 0.05% 392
2020
Q2 		$1.02M Buy
+8,404
New +$946K 0.02% 553
2020
Q1 		– Sell
-14,643
Closed -$1.29M – 1113
2019
Q4 		$1.29M Sell
14,643
-1,116
-7% -$98.2K 0.06% 467
2019
Q3 		$1.26M Buy
+15,759
New +$1.27M 0.03% 727
2019
Q1 		– Sell
-5,034
Closed -$548K – 768
2018
Q4 		$548K Sell
5,034
-16,953
-77% -$1.97M 0.02% 132
2018
Q3 		$2.81M Buy
21,987
+6,858
+45% +$848K 0.11% 194
2018
Q2 		$1.71M Buy
15,129
+2,454
+19% +$270K 0.08% 344
2018
Q1 		$1.42M Buy
12,675
+749
+6% +$95.2K 0.08% 320
2017
Q4 		$1.76M Buy
11,926
+4,738
+66% +$602K 0.12% 190
2017
Q3 		$842K Buy
7,188
+461
+7% +$58.9K 0.07% 379
2017
Q2 		$873K Buy
6,727
+1,026
+18% +$128K 0.09% 303
2017
Q1 		$772K Buy
5,701
+1,275
+29% +$193K 0.09% 281
2016
Q4 		$635K Buy
4,426
+145
+3% +$18.5K 0.09% 289
2016
Q3 		$506K Buy
4,281
+296
+7% +$35.6K 0.08% 362
2016
Q2 		$422K Buy
3,985
+3,307
+488% +$369K 0.07% 412
2016
Q1 		$76K Buy
678
+21
+3% +$2.66K 0.02% 703
2015
Q4 		$103K Buy
+657
New +$95.6K 0.02% 579

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Pacer Advisors's UTHR Position: Q1 2026 in Review

Pacer Advisors increased its United Therapeutics (UTHR) stake by 0.69% in Q1 2026, buying an estimated $833K and bringing the position to 243,545 shares worth $144M. The position accounts for 0.41% of the portfolio, ranked #61.

Pacer Advisors first reported a position in UTHR in Q4 2015 and has held it in 39 quarters since. The position peaked at $211M in Q4 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Pacer Advisors held 243,545 shares of United Therapeutics worth $144M as of Q1 2026.
  • Pacer Advisors bought 1,673 United Therapeutics shares in Q1 2026, an estimated $833K.
  • United Therapeutics made up 0.41% of Pacer Advisors's portfolio in Q1 2026, its #61 holding.
  • Pacer Advisors first reported a position in United Therapeutics in Q4 2015 and has held it in 39 quarters since.
  • Pacer Advisors's United Therapeutics position peaked at $211M in Q4 2024.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.